10-K: GT Biopharma Reports Full Year 2024 Results, Highlights Clinical Progress and Financial Position

GT Biopharma's 2024 10-K filing reveals ongoing clinical development of its TriKE platform, challenges in maintaining Nasdaq listing compliance, and a net loss of $13.2 million.

Summary

• GT Biopharma, a clinical-stage biopharmaceutical company, filed its Form 10-K for the year ended December 31, 2024.
• The company is focused on developing immuno-oncology products using its TriKE and Dual Targeting TriKE platforms.
• GTB-3650, a TriKE targeting CD33, received FDA clearance for its IND application and started study enrollment on January 21, 2025, targeting patients with relapsed/refractory AML and high-grade MDS.
• GTB-5550, a B7-H3 targeted TriKE, is advancing through preclinical studies with a pre-IND packet submitted to the FDA in October 2023.
• The company reported a net loss of $13.2 million for the year ended December 31, 2024, and has an accumulated deficit of approximately $695 million.
• As of December 31, 2024, GT Biopharma had approximately $4.0 million in cash and cash equivalents and a working capital deficit of $1.7 million.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• GT Biopharma received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement and is working on a plan to regain compliance.
• The company relies on third-party contract manufacturing operations, including Cytovance Biologics, Inc., a related party.
• GT Biopharma is involved in legal proceedings, including an arbitration demand against its former CFO and a lawsuit filed by a former interim CEO.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is clinical progress, the financial situation is concerning, and there are ongoing legal challenges. The Nasdaq listing issue adds further uncertainty.

Positives

• FDA clearance of the IND application for GTB-3650 and commencement of study enrollment.
• Advancement of GTB-5550 through preclinical studies and submission of a pre-IND packet to the FDA.
• Exclusive rights to the TriKE platform and ongoing efforts to generate additional intellectual property.
• Settlement of the Berk matter, removing a potential legal overhang.

Negatives

• Net loss of $13.2 million for the year ended December 31, 2024.
• Accumulated deficit of approximately $695 million.
• Working capital deficit of $1.7 million as of December 31, 2024.
• Substantial doubt about the company's ability to continue as a going concern.
• Notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement.
• Ongoing legal proceedings, including an arbitration demand against its former CFO.

Risks

• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The company may not be able to obtain additional financing on acceptable terms or at all.
• Failure to maintain compliance with Nasdaq's continued listing requirements could result in delisting of the common stock.
• Clinical drug development is costly, time-consuming, and uncertain.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or difficulties.
• The company is involved in legal proceedings, which could be costly and time-consuming.
• The company's products may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval.

Future Outlook

The company anticipates its direct clinical and preclinical expenses to increase in 2025 as its next generation GTB-3650 camelid nanobody product is in the clinic and plans to complete the product development of GTB-5550 in 2025.

Industry Context

The report acknowledges the highly competitive market for therapeutic immuno-oncology products, with competition from major pharmaceutical and biotechnology companies, universities, and research institutions.

Comparison to Industry Standards

• The document mentions that the market value of bispecific antibodies, cancer vaccines, checkpoint modulators, cell therapies, and oncolytic viruses globally has increased sharply in the past 10 years with nearly $29 billion in 2019 compared to $370 million in 2010.
• The document references Global Data, Thematic Research: Immuno-Oncology (March 2021), as of December 2020, there are 4,822 industry-sponsored clinical trials for immuno-oncology with 422 drugs in development.
• The document mentions that Phase 2 trials constitute the majority of the IO pipeline, followed by early-stage molecules in Phase 1/2 and Phase 1.
• The document mentions that for late-stage pipeline products, 484 clinical trials are ongoing in Phase 3, and 51 are in Phase 2/3 development.
• The document mentions that there are currently 22 marketed immuno-oncology agents.
• The document mentions that cancer vaccine products lead the category with 9 products followed by checkpoint modulators with 8 approved drugs.
• The document mentions that the indications with the most marketed IO agents in the United States are metastatic melanoma and non-small cell lung cancer, with 6 approved products each.

Legal Proceedings

• The Company filed an AAA Arbitration Demand against Manu Ohri, its former Chief Financial Officer, for breach of fiduciary duties and breach of contract.
• Former interim Chief Executive Officer, Dr. Gregory Berk filed a lawsuit in the U.S. District Court for the District of Massachusetts alleging that the Company discriminated and retaliated against Dr. Berk for engaging in protected whistleblowing activity in violation of the Sarbanes Oxley Act (SOX).
• TWF Global, LLC (TWF) filed a Complaint in the California Superior Court for the County of Los Angeles naming the Company as defendant alleging that TWF is the holder of two Convertible Promissory Notes (Notes) and that the Company did not deliver shares of common stock due on conversion in February 2021.
• The Company made an arbitration demand upon Michael Handelman, its former Chief Financial Officer, asserting that he breached his fiduciary duty by misappropriating Company funds and shares of common stock, among other things.

Related Party Transactions

• The company has significant transactions with Cytovance Biologics, Inc., a related party, for research and development services.
• The company has agreements with the Regents of the University of Minnesota for scientific research and patent licensing.

Stakeholder Impact

• Shareholders face the risk of dilution from potential future equity financings.
• Employees may be affected by potential cost-cutting measures if the company is unable to secure additional financing.
• The company's ability to develop and commercialize its product candidates could impact patients with hematologic malignancies and solid tumors.
• Suppliers and creditors may be affected by the company's financial condition and ability to meet its obligations.

Next Steps

• Continue clinical development of GTB-3650 and GTB-5550.
• Seek additional financing to fund operations.
• Implement a plan to regain compliance with Nasdaq listing requirements.
• Manage ongoing legal proceedings.

Key Dates

Keywords

TriKE, GTB-3650, GTB-5550, immuno-oncology, clinical stage, biopharmaceutical, FDA, IND, AML, MDS, B7-H3, Nasdaq, Cytovance, University of Minnesota, warrants, clinical trials, intellectual property